Biotechnology

Crescendo Biologics Announces That Zai Lab Has Achieved Proof-of-Concept for ZL-1102 (Humabody®, CB001) in a Phase 1b Clinical Trial in Psoriasis Patients

Thursday, October 21, 2021 - 8:00am

The Phase 1b trial was a first-in-human study to evaluate the safety, pharmacokinetics and efficacy of a topical formulation of ZL-1102 in adults with mild-to-moderate chronic plaque psoriasis (CPP).

Key Points: 
  • The Phase 1b trial was a first-in-human study to evaluate the safety, pharmacokinetics and efficacy of a topical formulation of ZL-1102 in adults with mild-to-moderate chronic plaque psoriasis (CPP).
  • Further information can be found in the press release issued by Zai Lab on 20 October 2021.
  • Theodora Harold, Chief Executive Officer at Crescendo, said: This is a very exciting day for Crescendo.
  • Under the terms of that agreement, Crescendo granted to Zai Lab a worldwide exclusive license to develop and commercialize ZL-1102 for all indications.

Ipsen Delivers Strong Sales Growth for the First Nine Months and Improves Its Full-Year Guidance

Thursday, October 21, 2021 - 6:36am

Italy: sales of 96.5m, up by 16.4% 8 , were mainly a result of a solid Cabometyx uptake and the Somatuline performance.

Key Points: 
  • Italy: sales of 96.5m, up by 16.4% 8 , were mainly a result of a solid Cabometyx uptake and the Somatuline performance.
  • U.K.: sales reached 90.0m, an increase of 2.8% 8 , mainly driven by a strong Somatuline performance, partly offset by lower volumes of Decapeptyl.
  • Spain: sales of 89.2m reflected growth of 10.1% 8 , driven by market-share gains for Somatuline and Decapeptyl.
  • Strong Dysport sales reflected good performance in the aesthetics and therapeutics markets after the impact of COVID-19 in 2020.

Oncodesign and TiumBio Sign Collaboration Agreement for R&D of Fibrosis Drug Candidates

Thursday, October 21, 2021 - 7:00am

Under this agreement, Oncodesign will be responsible for identification, chemical synthesis and optimization of Nanocyclix drug candidates and their early-stage analysis, while TiumBio will be responsible for the advanced evaluation of fibrotic efficacy of the drug candidates.

Key Points: 
  • Under this agreement, Oncodesign will be responsible for identification, chemical synthesis and optimization of Nanocyclix drug candidates and their early-stage analysis, while TiumBio will be responsible for the advanced evaluation of fibrotic efficacy of the drug candidates.
  • Also, TiumBio has secured an exclusive option to in-license global development and commercialization rights of the discovered drug candidates after their evaluation upon reaching predefined success criteria.
  • Philippe Genne, CEO and founder of Oncodesign, said: This new collaboration with TiumBio, an expert company in fibrosis in South-Korea, further expands the global reach of our unique technologies.
  • It is believed that this joint R&D collaboration, signed by TiumBio, which has strengths in fibrosis R&D, can be a catalyst to spur the development of fibrosis treatment.

VarmX Awarded Funding From the EIC Accelerator to Support Scale up and Manufacturing of VMX-C001

Thursday, October 21, 2021 - 6:00am

The EIC Accelerator aims to support start-ups and Small and Medium Enterprises (SMEs) in development and scale up of game-changing innovations.

Key Points: 
  • The EIC Accelerator aims to support start-ups and Small and Medium Enterprises (SMEs) in development and scale up of game-changing innovations.
  • VarmX was among 65 start-ups and SMEs selected, located across 16 countries, which will together receive 363 million of funding for breakthrough innovations.
  • Based on project assessment criteria of excellence, scale-up potential, and level of risk, a panel of expert independent evaluators and EIC jury members recommended that VarmX should be awarded the maximum allowed funding, subject to negotiation.
  • As part of the EIC community, VarmX will also receive further benefits, including coaching, mentoring, and access to investors and corporates.

Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Thursday, October 21, 2021 - 1:00am

The equity awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individuals employment compensation and were granted as an inducement material to his or her acceptance of employment with the Company.

Key Points: 
  • The equity awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individuals employment compensation and were granted as an inducement material to his or her acceptance of employment with the Company.
  • The options have an exercise price equal to $46.98 per share, the closing price of the Companys common stock as reported by Nasdaq on October 15, 2021.
  • Arcturus versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics.
  • Arcturus technologies are covered by its extensive patent portfolio (patents and patent applications issued in the U.S., Europe, Japan, China and other countries).

CDC ACIP Unanimously Votes to Provisionally Recommend Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) in Series with PNEUMOVAX ® 23 (Pneumococcal Vaccine Polyvalent) as an Option for Pneumococcal Vaccination in Appropriate Adults

Thursday, October 21, 2021 - 12:07am

In both groups, the ACIP voted to provisionally recommend vaccination either with a sequential regimen of VAXNEUVANCEfollowed by PNEUMOVAX23, or with a single dose of 20-valent pneumococcal conjugate vaccine.

Key Points: 
  • In both groups, the ACIP voted to provisionally recommend vaccination either with a sequential regimen of VAXNEUVANCEfollowed by PNEUMOVAX23, or with a single dose of 20-valent pneumococcal conjugate vaccine.
  • These updates would apply to adults who have not previously received a pneumococcal conjugate vaccine or whose previous pneumococcal vaccination history is unknown.
  • VAXNEUVANCE is contraindicated for individuals with a history of severe allergic reaction (e.g., anaphylaxis) to any component of VAXNEUVANCE or to diphtheria toxoid.
  • PNEUMOVAX 23 is contraindicated in individuals with a history of a hypersensitivity reaction to any component of PNEUMOVAX 23.

TriplePoint Venture Growth BDC Corp. to Announce 2021 Third Quarter Financial Results on Wednesday, November 3, 2021

Wednesday, October 20, 2021 - 10:41pm

TriplePoint Venture Growth BDC Corp. (NYSE: TPVG) (the Company), the leading financing provider to venture growth stage companies backed by a select group of venture capital firms in the technology, life sciences and other high growth industries, today announced it will release its financial results for its third quarter ended September 30, 2021 after market-close on Wednesday, November 3, 2021.

Key Points: 
  • TriplePoint Venture Growth BDC Corp. (NYSE: TPVG) (the Company), the leading financing provider to venture growth stage companies backed by a select group of venture capital firms in the technology, life sciences and other high growth industries, today announced it will release its financial results for its third quarter ended September 30, 2021 after market-close on Wednesday, November 3, 2021.
  • To listen to the call, investors and analysts should dial (844) 826-3038 (domestic) or +1 (412) 317-5184 (international) and ask to join the TriplePoint Venture Growth BDC Corp. call.
  • ABOUT TRIPLEPOINT VENTURE GROWTH BDC CORP.
    TriplePoint Venture Growth BDC Corp. is an externally-managed business development company focused on providing customized debt financing with warrants and direct equity investments to venture growth stage companies in technology and other high growth industries backed by a select group of venture capital firms.
  • For more information about TriplePoint Venture Growth BDC Corp., visit https://www.tpvg.com .

Moderna Announces FDA Authorization of a Booster Dose of Moderna’s COVID-19 Vaccine in the U.S.

Wednesday, October 20, 2021 - 10:37pm

The FDA also authorized a single booster dose of the Moderna COVID-19 Vaccine for individuals who have completed a primary vaccination with other authorized or approved COVID-19 vaccines.

Key Points: 
  • The FDA also authorized a single booster dose of the Moderna COVID-19 Vaccine for individuals who have completed a primary vaccination with other authorized or approved COVID-19 vaccines.
  • This emergency use authorization is supported by robust clinical evidence that a 50 g booster dose induces a strong immune response against COVID-19.
  • Notably, a booster dose of mRNA-1273 at the 50 g dose level boosted neutralizing titers significantly above the Phase 3 benchmark.
  • The safety profile following the booster dose was similar to that observed previously for dose 2 of mRNA-1273.

Aditxt Announces Closing of $4.25 Million Public Offering

Wednesday, October 20, 2021 - 10:31pm

Aditxt, Inc. (Aditxt) (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, announced today the closing of its previously announced underwritten public offering of 2,833,333 shares of its common stock at a public offering price of $1.50 per share, for gross proceeds of $4.25 million, before deducting underwriting discounts and offering expenses.

Key Points: 
  • Aditxt, Inc. (Aditxt) (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, announced today the closing of its previously announced underwritten public offering of 2,833,333 shares of its common stock at a public offering price of $1.50 per share, for gross proceeds of $4.25 million, before deducting underwriting discounts and offering expenses.
  • Aditxt plans to use a portion of the net of underwriting discounts proceeds of approximately $3.91 million from this offering to fund certain obligations under its previously announced Transaction Agreement with AiPharma Global Holdings entered into on October 4, 2021.
  • Sheppard, Mullin, Richter & Hampton LLP acted as counsel to Aditxt and Lucosky Brookman LLP acted as counsel to the underwriter.
  • The offering of the common stock described above is being made pursuant to an effective shelf registration statement on Form S-3 (File No.

Catalent, Inc. Announces First Quarter Fiscal Year 2022 Earnings Conference Webcast

Wednesday, October 20, 2021 - 10:15pm

The Companys management will host a webcast to discuss the results at 8:15 a.m.

Key Points: 
  • The Companys management will host a webcast to discuss the results at 8:15 a.m.
  • Catalent invites all interested parties to listen to the webcast, which will be accessible through Catalents website at http://investor.catalent.com .
  • A supplemental slide presentation will also be available in the Investors section of Catalents website prior to the start of the webcast.
  • The webcast replay, along with the supplemental slides, will be available for 90 days in the Investors section at www.catalent.com .